StockData

MacroGenics vs Arcus Biosciences

MGNX and RCUS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MGNX and RCUS compare

Arcus Biosciences is the larger company, worth 16 times as much as MacroGenics ($2.1B against $138M).

MacroGenics grew revenue faster over the last twelve months (11.7% versus −55.3% for Arcus Biosciences).

MacroGenics keeps more of each dollar of sales as profit, with a net margin of −8.7% compared with −393% at Arcus Biosciences.

MacroGenics scores higher on the StockData Score (5 against 3 for Arcus Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMGNXRCUS
Size and price
Market cap$138M$2.1B
Share price$2.17$16.86
Change, 1 year35.6%−14.8%
Change, 5 years−88.4%−63.6%
Beta (5Y)0.451.09
Employees293601
StockData Score
Total score5 (better)3
Valuation score00
Growth score12 (better)
Performance score3 (better)0
Health score11
Dividend score00
Valuation
P/S0.8× (better)18.3×
P/B3.2× (better)4.6×
FCF yield−47.4%−22.1% (better)
Fair value–$7.35
Margin of safety–−129%
Growth
Revenue growth (TTM)11.7% (better)−55.3%
Revenue growth, 5Y average7.3%25.9% (better)
Profitability
Operating margin−24.3% (better)−415%
Net margin−8.7% (better)−393%
FCF margin−39.1% (better)−406%
Return on equity−32.6% (better)−90.8%
Financial health
Interest coverage−2.4× (better)−44.2×
Current ratio2.963.82 (better)
Altman Z-score−4.00−0.67 (better)
Piotroski F-score4 (better)1
Dividends and buybacks
Buyback yield–−13.4%
Shareholder yield0.00% (better)−13.4%
Ownership
Held by institutions76.4%96.3%
Held by insiders6.2%31.7%
Insider net buying, 12 months−$129K (better)−$9.3M
Short interest, % of float8.3%15.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.